BiomX Inc. to Become Tessera Defense and Homeland Security Inc.
The new name completes the Company’s transformation into a defense and homeland security technology group, built through the acquisitions and investments it has made over the past year.
A tessera is a single tile in a mosaic. Alone it is a fragment; set alongside others, it becomes part of a complete picture. The name describes how the Company is assembled: individual technology companies, each substantial in its own right, brought together into one architecture for prediction, detection, analysis and response.
The effective date was chosen deliberately.
“We did not choose this date lightly, and we do not take it lightly,” said
The Company’s portfolio today includes
What the Name Change Means for Stockholders
The name change does not affect the rights of the Company’s stockholders. No action is required by stockholders, and no exchange of book-entry positions or stock certificates is necessary. The Company’s common stock will be identified by CUSIP number 09090D 608. The Company’s common stock will continue to trade under the symbol “PHGE” until the effective time of the name change.
As previously announced on
About the Company
BiomX Inc., to be renamed Tessera Defense and Homeland Security Inc., is a technology group focused on defense and homeland security. Through its subsidiaries and investments, the Company develops and deploys threat detection, AI-powered analysis and related technologies for defense, security and critical infrastructure customers. The Company’s common stock is listed on the NYSE American.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing and effectiveness of the name change, the change of the Company’s ticker symbol, the reverse stock split, and the Company’s strategy and portfolio. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, including the risk that the name change or the reverse stock split does not become effective when anticipated, and those risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
Media Contact: Yair Ohayon, Yairo@biomx.com